天大藥業(00455.HK)中期歸母淨利潤上升4.2%至260萬港元
格隆匯11月28日丨天大藥業(00455.HK)發佈中期業績,截至2019年9月30日止6個月,公司實現收入2.623億港元,同比輕微下跌1.4%;母公司股東應占溢利約為260萬港元,同比上升4.2%;基本每股盈利0.12港仙;不派息。
報告期內,公司全資附屬公司天大藥業(珠海)有限公司銷售收入由去年同期上升39.5%至報告期約1.108億港元。其中,主要產品託平(纈沙坦膠囊)及託恩(布洛芬混懸液及滴劑)的銷售收入較去年同期分別上升52.3%及41.1%。天大藥業(珠海)溢利貢獻由去年同期增加55.4%。
此外,雲南盟生藥業有限公司(盟生藥業)銷售收入由去年同期下跌23.7%,銷售收入下跌的主要原因為國家政策影響及對部分地區售價的調低,當中旗艦產品注射用腦蛋白水解物的銷量與去年同期同比下跌近16.6%,注射用腦蛋白水解物的銷售金額由去年同期下跌至約1.059億港元,導致盟生藥業溢利由去年同期下跌35.1%。然而,由於集團成功為盟生藥業所分派的股息預扣税申辦減免,於報告期回撥股息預扣税約160萬港元。扣除非控股權益,盟生藥業溢利貢獻為約730萬港元,較去年同期減少10.8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.